Literature DB >> 22740394

Neutralizing antibody escape during HIV-1 mother-to-child transmission involves conformational masking of distal epitopes in envelope.

Leslie Goo1, Caitlin Milligan, Cassandra A Simonich, Ruth Nduati, Julie Overbaugh.   

Abstract

HIV-1 variants transmitted to infants are often resistant to maternal neutralizing antibodies (NAbs), suggesting that they have escaped maternal NAb pressure. To define the molecular basis of NAb escape that contributes to selection of transmitted variants, we analyzed 5 viruses from 2 mother-to-child transmission pairs, in which the infant virus, but not the maternal virus, was resistant to neutralization by maternal plasma near transmission. We generated chimeric viruses between maternal and infant envelope clones obtained near transmission and examined neutralization by maternal plasma. The molecular determinants of NAb escape were distinct, even when comparing two maternal variants to the transmitted infant virus within one pair, in which insertions in V4 of gp120 and substitutions in HR2 of gp41 conferred neutralization resistance. In another pair, deletions and substitutions in V1 to V3 conferred resistance, but neither V1/V2 nor V3 alone was sufficient. Although the sequence determinants of escape were distinct, all of them involved modifications of potential N-linked glycosylation sites. None of the regions that mediated escape were major linear targets of maternal NAbs because corresponding peptides failed to compete for neutralization. Instead, these regions disrupted multiple distal epitopes targeted by HIV-1-specific monoclonal antibodies, suggesting that escape from maternal NAbs occurred through conformational masking of distal epitopes. This strategy likely allows HIV-1 to utilize relatively limited changes in the envelope to preserve the ability to infect a new host while simultaneously evading multiple NAb specificities present in maternal plasma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22740394      PMCID: PMC3446598          DOI: 10.1128/JVI.00953-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  85 in total

1.  Antibody-dependent cellular cytotoxicity and neutralizing activity in sera of HIV-1-infected mothers and their children.

Authors:  K Broliden; E Sievers; P A Tovo; V Moschese; G Scarlatti; P A Broliden; C Fundaro; P Rossi
Journal:  Clin Exp Immunol       Date:  1993-07       Impact factor: 4.330

2.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.

Authors:  T Muster; F Steindl; M Purtscher; A Trkola; A Klima; G Himmler; F Rüker; H Katinger
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

3.  An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.

Authors:  P J Klasse; J A McKeating; M Schutten; M S Reitz; M Robert-Guroff
Journal:  Virology       Date:  1993-09       Impact factor: 3.616

4.  Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change.

Authors:  M Thali; M Charles; C Furman; L Cavacini; M Posner; J Robinson; J Sodroski
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

5.  Features of HIV-1 that could influence maternal-child transmission.

Authors:  S C Kliks; D W Wara; D V Landers; J A Levy
Journal:  JAMA       Date:  1994-08-10       Impact factor: 56.272

6.  Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.

Authors:  C T Wild; D C Shugars; T K Greenwell; C B McDanal; T J Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

7.  Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies.

Authors:  N K Back; L Smit; M Schutten; P L Nara; M Tersmette; J Goudsmit
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

8.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

Authors:  P Roben; J P Moore; M Thali; J Sodroski; C F Barbas; D R Burton
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

9.  Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates.

Authors:  G Scarlatti; J Albert; P Rossi; V Hodara; P Biraghi; L Muggiasca; E M Fenyö
Journal:  J Infect Dis       Date:  1993-07       Impact factor: 5.226

10.  Independent variation and positive selection in env V1 and V2 domains within maternal-infant strains of human immunodeficiency virus type 1 in vivo.

Authors:  S L Lamers; J W Sleasman; J X She; K A Barrie; S M Pomeroy; D J Barrett; M M Goodenow
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

View more
  18 in total

1.  Immunological mechanisms of inducing HIV immunity in infants.

Authors:  Genevieve G Fouda; Kristina De Paris; Ofer Levy; Arnaud Marchant; Glenda Gray; Sallie Permar; Mary Marovich; Anjali Singh
Journal:  Vaccine       Date:  2019-11-21       Impact factor: 3.641

2.  Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.

Authors:  Zakiya M Qualls; Alok Choudhary; William Honnen; Raja Prattipati; James E Robinson; Abraham Pinter
Journal:  J Virol       Date:  2018-02-12       Impact factor: 5.103

3.  Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission.

Authors:  Sallie R Permar; Youyi Fong; Nathan Vandergrift; Genevieve G Fouda; Peter Gilbert; Robert Parks; Frederick H Jaeger; Justin Pollara; Amanda Martelli; Brooke E Liebl; Krissey Lloyd; Nicole L Yates; R Glenn Overman; Xiaoying Shen; Kaylan Whitaker; Haiyan Chen; Jamie Pritchett; Erika Solomon; Emma Friberg; Dawn J Marshall; John F Whitesides; Thaddeus C Gurley; Tarra Von Holle; David R Martinez; Fangping Cai; Amit Kumar; Shi-Mao Xia; Xiaozhi Lu; Raul Louzao; Samantha Wilkes; Saheli Datta; Marcella Sarzotti-Kelsoe; Hua-Xin Liao; Guido Ferrari; S Munir Alam; David C Montefiori; Thomas N Denny; M Anthony Moody; Georgia D Tomaras; Feng Gao; Barton F Haynes
Journal:  J Clin Invest       Date:  2015-06-08       Impact factor: 14.808

Review 4.  Antibodies for prevention of mother-to-child transmission of HIV-1.

Authors:  Genevieve G Fouda; M Anthony Moody; Sallie R Permar
Journal:  Curr Opin HIV AIDS       Date:  2015-05       Impact factor: 4.283

5.  Comprehensive Mapping of HIV-1 Escape from a Broadly Neutralizing Antibody.

Authors:  Adam S Dingens; Hugh K Haddox; Julie Overbaugh; Jesse D Bloom
Journal:  Cell Host Microbe       Date:  2017-06-01       Impact factor: 21.023

6.  HIV-1 Neutralizing Antibodies with Limited Hypermutation from an Infant.

Authors:  Cassandra A Simonich; Katherine L Williams; Hans P Verkerke; James A Williams; Ruth Nduati; Kelly K Lee; Julie Overbaugh
Journal:  Cell       Date:  2016-06-23       Impact factor: 41.582

7.  A combination of broadly neutralizing HIV-1 monoclonal antibodies targeting distinct epitopes effectively neutralizes variants found in early infection.

Authors:  Leslie Goo; Zahra Jalalian-Lechak; Barbra A Richardson; Julie Overbaugh
Journal:  J Virol       Date:  2012-07-25       Impact factor: 5.103

8.  The Impact of IgG transplacental transfer on early life immunity.

Authors:  Genevieve G Fouda; David R Martinez; Geeta K Swamy; Sallie R Permar
Journal:  Immunohorizons       Date:  2018-01-01

Review 9.  Engineering broadly neutralizing antibodies for HIV prevention and therapy.

Authors:  Casey K Hua; Margaret E Ackerman
Journal:  Adv Drug Deliv Rev       Date:  2016-01-29       Impact factor: 15.470

10.  A diverse collection of B cells responded to HIV infection in infant BG505.

Authors:  Cassandra Simonich; Mackenzie M Shipley; Laura Doepker; Theodore Gobillot; Meghan Garrett; Evan M Cale; Brianna Hennessy; Hannah Itell; Vrasha Chohan; Nicole Doria-Rose; Ruth Nduati; Julie Overbaugh
Journal:  Cell Rep Med       Date:  2021-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.